Tisagenlecleucel与历史标准治疗在儿童及年轻成人复发/难治性B细胞前体急性淋巴细胞白血病中的比较
在缺乏随机对照试验的情况下,该研究基于三项tisagenlecleucel研究(ELIANA、ENSIGN、CCTL019B2001X)与德国/奥地利三个登记处的患者水平数据,采用倾向评分加权调整历史对照的混杂因素,比较tisagenlecleucel与标准治疗(SOC)的疗效。调整后队列可比性高(所有预设混杂因素绝对SMD≤0.1),tisagenlecleucel在OS和ORR上优于SOC,EFS和RFS数值上更优但RFS未达统计学显著。
要点
- 调整后tisagenlecleucel组OS风险比为0.54(95%CI 0.41-0.71,p<0.001)。
- 调整后ORR的OR为1.99(95%CI 1.33-2.97,p<0.001)。
- RFS风险比0.77(95%CI 0.51-1.18,p=0.233),未达统计学显著。
核心结论
- 在调整混杂因素后,tisagenlecleucel在复发/难治性急性淋巴细胞白血病中显示出优于SOC的OS和ORR,支持其优效性。
研究设计与样本
- 非随机比较研究,基于三项tisagenlecleucel研究(ELIANA、ENSIGN、CCTL019B2001X)的患者水平数据与德国/奥地利三个登记处的历史对照进行比较。
- 采用倾向评分加权(精细分层权重)调整经系统文献综述确定的 relevant 混杂因素。
主要发现
- 调整后所有预设混杂因素的绝对SMD≤0.1,队列可比性高。
- OS(意向治疗ITT,调整后)风险比为0.54(95%CI 0.41-0.71,p<0.001);EFS(全分析集FAS,未调整)风险比为0.67(95%CI 0.52-0.86,p=0.001);RFS(FAS,未调整)风险比为0.77(95%CI 0.51-1.18,p=0.233)。
- 2年OS概率:tisagenlecleucel组59.49% vs SOC组36.16%;2年EFS概率:42.31% vs 30.23%;2年RFS概率:59.60% vs 54.57%。
- ORR(ITT,调整后)的OR为1.99(95%CI 1.33-2.97,p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the absence of randomized controlled trials comparing tisagenlecleucel vs. standard of care (SOC) in pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia (r/r ALL), the objective was to compare the efficacy of tisagenlecleucel with historical controls from multiple disease registries using patient-level adjustment of the historical controls. The analysis is based on patient-level data of three tisagenlecleucel studies (ELIANA, ENSIGN and CCTL019B2001X) vs. three registries in Germany/Austria. Statistical analyses were fully pre-specified and propensity score weighting of the historical controls by fine stratification weights was used to adjust for relevant confounders identified by systematic literature review. Results showed high comparability of cohorts after adjustment with absolute SMD ≤ 0.1 for all pre-specified confounders and favorable outcomes for tisagenlecleucel compared to SOC for all examined endpoints. Hazard ratios for OS(Intention to treat)ITT,adjusted, EFS(Full analysis set)FAS,naïve and RFSFAS,naïve were 0.54 (95% CI: 0.41-0.71, p < 0.001), 0.67 (0.52-0.86, p = 0.001) and 0.77 (0.51-1.18, p = 0.233). The OSITT, adjusted, EFSFAS,naïve and RFSFAS,naive survival probability at 2 years was 59.49% for tisagenlecleucel vs. 36.16% for SOC population, 42.31% vs. 30.23% and 59.60% vs. 54.57%, respectively. Odds ratio for ORRITT,adjusted was 1.99 (1.33-2.97, p < 0.001). Results for OS and ORR were statistically significant after adjustment for confounders and provide evidence supporting a superiority of tisagenlecleucel in r/r ALL given the good comparability of cohorts after adjustment for confounders.
引用
- V Stackelberg A, Jäschke K, Jousseaume E, et al. Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Leukemia. 2023. PMID: 37880478. doi:10.1038/s41375-023-02042-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。